Nexium, Prilosec Lawsuits Getting Prepped for Trial

Last modified:
Fact Checked
Fact-Checked

Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

scales of justice in court room

The first of more than 4,500 proton pump inhibitor lawsuits will go to trial on September 21, 2020. The lawsuits are against the makers of popular heartburn medicines, such as Prilosec, Nexium, Prevacid and Protonix.

Lawyers for the consumers had been trying to negotiate a trial date since September 2017. But, they said, the lawyers for the drug companies had not been cooperative.

Judge Claire C. Cecchi is overseeing the lawsuits. She had urged the lawyers for both sides to pick a trial date.

The parties initially reached an agreement for a May 2020 trial. But the date was pushed back four months after the court reviewed the logistics of the case, according to a case management order issued on June 20, 2018.

The outcomes of the early trials (known as bellwether trials) can influence settlement negotiations. They can also lead to cases being dismissed.

A total of 4,517 PPI lawsuits were pending in the New Jersey federal court as of June 15, 2018. A judicial panel had grouped these cases into multidistrict litigation (MDL) in August 2017. The number of lawsuits continues to grow.

People take PPIs to reduce stomach acid. Studies have linked the powerful medicines to kidney injury.

PPI side effects include acute interstitial nephritis and kidney failure. These injuries can be permanent, leading to long-term complications and death.

PPI lawsuits say the drugmakers knew about these kidney risks. But they failed to warn consumers.

Are you suffering from side effects after taking a proton pump inhibitor? Get a Free Case Review
  •  
  •  
  •  

Did you find Drugwatch helpful?

Yes No
Written by Kristin Compton Kristin Compton Writer

Kristin Compton's background is in legal studies. She worked as a paralegal before joining Drugwatch as a writer and researcher. She was also a member of the National Association of Legal Assistance. A mother and longtime patient, she has firsthand experience of the harmful effects prescription drugs can have on women and their children. Some of her qualifications include:

  • Bachelor of Arts in Legal Studies | Pre-Law from University of West Florida
  • Past employment with The Health Law Firm and Kerrigan, Estess, Rankin, McLeod & Thompson LLC
  • Personal experience battling severe food allergies, asthma and high-risk pregnancies
More About Kristin Compton
Emily Miller
Edited By Emily Miller Editor

8 Cited Research Articles

  1. Klepser, D.G. et al. (2013, July 16). Proton pump inhibitors and acute kidney injury: a nested case-control study. U.S. National Library of Medicine. NIH. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23865955
  2. Medline Plus. (2017, August 1). Interstitial nephritis. U.S. National Library of Medicine. NIH. Retrieved from https://medlineplus.gov/ency/article/000464.htm
  3. U.S. Judicial Panel on Multidistrict Litigation. (2017, August 2). Transfer Order. In Re: Proton-Pump Inhibitor Products Liability Litigation (No. II). MDL No. 2789. Retrieved from http://www.jpml.uscourts.gov/sites/jpml/files/MDL-2789-Initial_Transfer-07-17.pdf
  4. U.S. Judicial Panel on Multidistrict Litigation. (2018, May 15). MDL Statistics Report – Distribution of Pending MDL Dockets by District. Retrieved from http://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-May-15-2018.pdf
  5. U.S. District Court District of New Jersey. (2018, May 18). Case Management Order No. 15 on May 1, 2018 Status Conference. In Re: Proton-Pump Inhibitor Products Liability Litigation (No. II). MDL No. 2789. Retrieved from https://jc6kx1c9izw3wansr3nmip8k-wpengine.netdna-ssl.com/wp-content/uploads/2018-05-18-Order.pdf
  6. DLA Piper. (2018, April 27). Defendants’ Letter Brief in Support of Proposed Scheduling Order. In Re: Proton-Pump Inhibitor Products Liability Litigation (No. II). MDL No. 2789. Retrieved from https://jc6kx1c9izw3wansr3nmip8k-wpengine.netdna-ssl.com/wp-content/uploads/2018-04-27-Defendant-Letter.pdf
  7. Seeger Weiss LLP. (2018, April 27). Proposed Scheduling Order. In Re: Proton-Pump Inhibitor Products Liability Litigation (No. II). MDL No. 2789. Retrieved from https://jc6kx1c9izw3wansr3nmip8k-wpengine.netdna-ssl.com/wp-content/uploads/2018-04-27-Plaintiff-Letter.pdf
  8. U.S. District Court District of New Jersey. (2018, June 20). Case Management Order No. 16 on June 12, 2018 Status Conference. In Re: Proton-Pump Inhibitor Products Liability Litigation. Retrieved from http://www.njd.uscourts.gov/sites/njd/files/MDL16.pdf
View All Sources

Related Articles

More from Related Articles
Call to speak with a legal expert
Who Am I Calling?

Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.

Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.

(844) 440-8662

To contact Drugwatch Managing Editor Kevin Connolly, call (855) 839-9780.